Stockreport

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Cong...

Crinetics Pharmaceuticals, Inc.  (CRNX) 
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm Check Earnings Report
PDF Atumelnant (80 mg) Achieved a 67% Mean Reduction in Androstenedione Levels While Simultaneously Enabling 88% of Participants Completing 12 Weeks of Treatment to Success [Read more]